Drugs / tropicamide
tropicamide
also known as
Bistropamide · Mydriacyl · Mydriafair · NH004 · Nods · NSC-757372 · RO-1-7683 · Tropicacyl · +6 more
Small molecule targets CHRM3 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | MYDRIACYL | — | 1960-02-23 | fda.gov ↗ |
Trials 17
1959196019611962196319641965196619671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06288321 | Aug 2022 → Mar 2023 | retinopathy of prematurity | The University of Hong Kong | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07075224 | Nov 2025 | — | Unither Pharmaceuticals, France | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT03201562 | Apr 2017 → May 2018 | presbyopia | LENZ Therapeutics, Inc | Completed | Met primary |
| Phase 2 | NCT01844648 | Apr 2013 → Oct 2015 | — | NeuroHealing Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00761137 | Mar 2008 → Jun 2010 | secondary Parkinson disease | NeuroHealing Pharmaceuticals Inc. | Completed | Missed primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT03751631 | Nov 2018 → Jan 2019 | — | Eyenovia Inc. | Completed | No outcome recorded |
| Phase 49 trials · 4 met primary | ||||||
| Phase 4 | NCT06366217 | Oct 2024 → Jul 2025 | abnormal pupillary function | University of California, San Francisco | Completed | Met primary |
| Phase 4 | NCT06217796 | Nov 2023 → Jan 2024 | — | Eyenovia Inc. | Completed | No outcome recorded |
| Phase 4 | NCT05238233 | Apr 2022 → Jan 2023 | anisocoria | Prisma Health-Upstate | Completed | No outcome recorded |
| Phase 4 | NCT05043077 | Sep 2021 → Jan 2023 | retinopathy of prematurity | Aristotle University Of Thessaloniki | Completed | Met primary |
| Phase 4 | NCT04907474 | May → Jun 2021 | — | Eyenovia Inc. | Completed | Met primary |
| Phase 4 | NCT04623684 | Mar → Sep 2020 | retinopathy of prematurity | Aristotle University Of Thessaloniki | Completed | No outcome recorded |
| Phase 4 | NCT02177539 | May → Aug 2014 | refractive error | Pontificia Universidad Catolica de Chile | Unknown | No outcome recorded |
| Phase 4 | NCT04838665 | Sep 2011 | retinopathy of prematurity | University of the Philippines | Completed | No outcome recorded |
| Phase 4 | NCT00877175 | Mar → May 2009 | — | Khon Kaen University | Completed | Met primary |
| Phase not applicable2 trials | ||||||
| — | NCT06914063 | Mar → Jun 2025 overdue | cycloplegia | Superior University | Active not recruiting | No outcome recorded |
| — | NCT07495670 | Nov 2024 → Jan 2025 | diabetes mellitus, diabetic retinopathy | Burapha University | Completed | No outcome recorded |
| Comparator or background therapy15 trials | ||||||
| Phase 1 | NCT03139708 Background | Sep 2016 → Oct 2017 | — | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 3 | NCT04932213 Comparator | Jul → Nov 2021 | type 1 diabetes mellitus, type 2 diabetes mellitus | Semnan University of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT04396301 Comparator | Feb → Aug 2019 | cataract, corneal disorder | Cairo University | Completed | No outcome recorded |
| Phase 3 | NCT02101359 Comparator | Jun 2011 → Jan 2013 | cataract | Laboratoires Thea | Completed | No outcome recorded |
| Phase 3 | NCT00642135 Comparator | Jan 2006 → Feb 2008 | — | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| Phase 3 | NCT00120432 Comparator | Dec 2004 → Jun 2005 | eye disorder | Khon Kaen University | Completed | No outcome recorded |
| Phase 4 | NCT06077682 Comparator | Sep 2023 → Sep 2024 | cycloplegia, esotropia, refractive error, vision disorder | Islamic Hospital, Jordan | Unknown | No outcome recorded |
| Phase 4 | NCT05442801 Comparator | Mar → Jun 2022 | cycloplegia | Islamic Hospital, Jordan | Completed | No outcome recorded |
| Phase 4 | NCT05771194 Background | Feb 2021 → Mar 2022 | eyelid disorder | Tianjin Medical University Eye Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04880928 Comparator | Aug 2020 → Sep 2021 | cataract | Medical University of Graz | Completed | No outcome recorded |
| Phase 4 | NCT03959176 Background | Jul 2019 | ocular hypertension | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 4 | NCT02373137 Background | Jan 2015 → Apr 2018 | corneal disorder | Oregon Health and Science University | Unknown | No outcome recorded |
| Phase 4 | NCT00541177 Comparator | Apr 2007 → Mar 2008 | myopia | Min-Sheng General Hospital | Unknown | No outcome recorded |
| — | NCT04040790 Background | Sep 2019 → Jun 2021 | vision disorder | University Ghent | Terminated | No outcome recorded Stop: Business |
| — | NCT02895074 Background | Aug 2014 → Jun 2015 | cataract | Sun Yat-sen University | Completed | No outcome recorded |
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 34 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tropicamide | “The active substances in Fydrane are: tropicamide 0.04 mg (anticholinergic), phenylephrine hydrochloride 0.62 mg (alpha sympathomimetic) and Lidocaine hydrochloride 2 mg (amide...” NCT04396301 ↗31“standard Mydrin-P (0.5% tropicamide / 0.5% phenylephrine HCl) which is the standard eyedrops used for dilation of pupil before retinopathy of prematurity examination.” NCT06288321 ↗ “Rapid-Onset Cycloplegic Drops (e.g., tropicamide with phenylephrine) to assess patient comfort, anxiety, and satisfaction with quicker onset and shorter duration.” NCT06914063 ↗ “Fixed combination of 0.34 % tropicamide and 2.5 % phenylephrine Hydrochloride (HCl) Eye drop Solution.” NCT07075224 ↗ “The compound tropicamide was administered once a day (Shentian Pharmaceutical Co., Ltd., China)” NCT05771194 ↗ “3 drops of tropicamide and phenylephrine were instilled 30 minutes before surgery.” NCT02101359 ↗ “tropicamide and phenylephrine hydrochloride ophthalmic spray 1%/2.5%” NCT06217796 ↗ “Tropicamide and Phenylephrine ophthalmic one drop” NCT03139708 ↗ “Tropicamide 1% and phenylephrine HCl 2.5%” NCT06366217 ↗ “Tropicamide 0.5%” NCT04880928 ↗ |
| Known as | Bistropamide | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200604 ↗ |
| Known as | Mydriacyl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200604 ↗ |
| Known as | Mydriafair | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200604 ↗ |
| Known as | NH004 | “Drug: NH004 tropicamide” NCT01844648 ↗ |
| Known as | Nods | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200604 ↗ |
| Known as | NSC-757372 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200604 ↗ |
| Known as | RO-1-7683 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200604 ↗ |
| Known as | Tropicacyl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200604 ↗ |
| Known as | Tropicamid | “eye drops (Tropicamid)” NCT04880928 ↗ |
| Known as | Tropicamida | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200604 ↗ |
| Known as | Tropicamide component of mydcombi | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200604 ↗ |
| Known as | Tropicamide component of paremyd | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200604 ↗ |
| Known as | Tropicamidum | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200604 ↗ |
| Known as | Visumidriatic | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200604 ↗ |
| Action | Inhibit | “Muscarinic acetylcholine receptor M3 antagonist” CHEMBL1200604 ↗1“tropicamide (muscarinic antagonist)” NCT07495670 ↗ |
| Modality | Small molecule | — CHEMBL1200604 ↗ |
| Route | Topical | “Group A received a single dose of 1% tropicamide and 10% phenylephrine eye drops, and Group B received three doses of the same drugs.” PMID 17205877 ↗ Nov 2006 |
| Target | CHRM3 | “Muscarinic acetylcholine receptor M3 antagonist” CHEMBL1200604 ↗ |